Skip to content

MiGBAN 2.0: Longitudinale Beobachtungsstudie bei Kindern und Jugendlichen mit Anorexia nervosa

MiGBAN 2.0: Longitudinale Beobachtungsstudie bei Kindern und Jugendlichen mit Anorexia nervosa - MiGBAN 2.0

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00040413
Enrollment
150
Registered
2026-05-21
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F50.0

Interventions

Group 1: The study examines how the disease, the gut microbiome, and various biological markers evolve over time in adolescents hospitalized with anorexia nervosa. To this end, questionnaires, blood,
these include questionnaires, blood, stool, and urine samples, as well as MRI scans for some of the participants. Control participants will be recruited through the patients’ friends and acquaintances

Sponsors

LVR-Universitätsklinikum Essen, Klinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters, Institut der Universität Duisburg-Essen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 18 Years

Inclusion criteria

Inclusion criteria: Patients: • female and male adolescents with anorexia nervosa (restrictive or binge-purge type) and atypical anorexia, • aged 12 to 18 years, • written informed consent from the patient and their legal guardian. Control subjects: • normal weight within the 20th to 80th BMI percentile, • no current psychiatric comorbidity, • no current or previous eating disorder, • aged 12 to 18 years, • written informed consent.

Exclusion criteria

Exclusion criteria: The following are excluded, amongst others: • organic brain disorders, • psychosis, • bipolar disorder, • substance use disorders, • an IQ < 80, • insufficient knowledge of German, • relevant organic diseases affecting the gastrointestinal tract or metabolism, • pregnancy, • use of antibiotics in the last 6 weeks, • contraindications to MRI.

Design outcomes

Primary

MeasureTime frame
Change in the median BMI (delta % mBMI) over 12 months following hospital admission.

Secondary

MeasureTime frame
Changes in body weight, energy and nutrient intake, AN psychopathology (EDI-2, EDE-Q), bacterial diversity and activity, inflammatory parameters, and depressive symptoms (PHQ-9, BDI-II). Further secondary endpoints: Changes in microbiome composition, intestinal permeability (zonulin), gastrointestinal symptoms, relapse probability, microRNAs, circRNAs, the urinary steroid metabolome, and the association of leptin with physical and psychological signs of starvation.

Countries

Germany

Contacts

Public ContactJochen Seitz

LVR-Universitätsklinikum Essen, Klinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters, Institut der Universität Duisburg-Essen

jochen.seitz@lvr.de+49-201-8707-465

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026